Skip to main content

Recombinant Cynomolgus CD25/IL-2R alpha His-tag Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 10716-RL

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
10716-RL-050

Key Product Details

Source

HEK293

Accession #

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived cynomolgus monkey CD25/IL-2R alpha protein
Glu22-Arg213, with a C-terminal 6-His tag

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Glu22

Predicted Molecular Mass

22 kDa

SDS-PAGE

40-45 kDa, under reducing conditions.

Activity

Measured by its ability to inhibit the IL-2-dependent proliferation of MO7e human megakaryocytic leukemic cells.
The ED50 for this effect is 0.20-1.60 μg/mL.

Scientific Data Images for Recombinant Cynomolgus CD25/IL-2R alpha His-tag Protein, CF

Recombinant Cynomolgus Monkey CD25/IL-2R alpha His-tag Protein Bioactivity.

Recombinant Cynomolgus Monkey CD25/IL-2R alpha His-tag (Catalog # 10716-RL) inhibits the IL-2 dependent proliferation of MO7e human megakaryocytic leukemic cells. The ED50 for this effect is 0.20-1.60 μg/mL.

Recombinant Cynomolgus Monkey CD25/IL-2R alpha His-tag Protein SDS-PAGE.

2 μg/lane of Recombinant Cynomolgus Monkey CD25/IL-2R alpha His-tag (Catalog # 10716-CV) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 40-45 kDa and 35- 40 kDa, repsectively.

Formulation, Preparation and Storage

10716-RL
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CD25/IL-2R alpha

IL-2 receptor alpha (IL-2R alpha), also known as CD25, is a 55 kDa type I membrane glycoprotein that belongs to the family of cytokine receptors that utilize the common gamma chain subunit (gamma c). Cynomolgus monkey IL-2R alpha cDNA encodes a 213 amino acid (aa) precursor with a 21 aa signal peptide and a 192 aa extracellular region. The ECD of cynomolgus monkey IL-2R alpha shares a 91.7% amino acid sequence identity with the ECD of huma IL-2R alpha. IL‑2R alpha is primarily expressed on activated T cells and on regulatory T cells (Treg) (1-3). IL-2R beta (CD122) and gamma c (IL-2R gamma /CD132) dimerize to form a constitutively expressed intermediate affinity IL-2 receptor (4, 5). By itself, IL-2R alpha binds IL-2 with low affinity. IL-2R alpha makes no contacts with IL-2R beta or gamma c, and only minor changes are observed in the IL-2 structure in response to receptor binding. These findings support the principal role of IL-2R alpha to deliver IL-2 to the signaling complex and act as regulator of signal transduction (6, 7). A soluble form of IL‑2R alpha can be generated by proteolytic cleavage of the cell surface receptor, rendering the T cell unresponsive to IL-2 (8, 9). Increased serum levels of soluble IL‑2R alpha are found in some cancers and immune disorders (10). IL-2R alpha is required for activation induced cell death (AICD) of naive T cells, a mechanism responsible for deleting autoreactive T cell clones (11, 12). IL-2R alpha is also required for the development of CD4+CD25+ Treg which suppresses autoreactive CD4+ T cells, thereby contributing to peripheral T cell homeostasis (11-13). Drug targeting of IL-2R alpha has been indicated to deplete Tregs and induce antitumor immunity in various syngeneic tumors (14, 15).

References

  1. Minami, Y. et al. (1993) Annu. Rev. Immunol. 11:245.
  2. Kovanen, P.E. and Leonard, W.J. (2004) Immunol. Rev. 202:67.
  3. Bluestone, J.A. and Tang, Q. (2005) Curr. Opin. Immunol. 17:638.
  4. Hatakeyama, M. et al. (1989) Science 244:551.
  5. Takeshita, T. et al. (1992) Science 257:379.
  6. Stauber, D. et al. (2006) Proc. Natl. Acad. Sci. U.S.A. 103:2788.
  7. Wang, X. et al. (2005) Science 310:1159.
  8. Wagner, D.K. et al. (1986) J. Immunol. 137:592.
  9. Schulz, O. et al. (1998) J. Exp. Med. 187:271.
  10. Witkowska, A.M. (2005) Mediat. Inflamm. 2005:121.
  11. Willerford, D.M. et al. (1995) Immunity 3:521.
  12. Van Parijs, L. et al. (1997) J. Immunol. 158:3738.
  13. Almeida, A.R.M. et al. (2002) J. Immunol. 169:4850.
  14. Zammarchi, F. et al. (2020) J. Immunother Cancer. 8:e000860.
  15. Maruoka, A.F. et al. (2020) J. Immunol. Res. 8:345.

Long Name

Interleukin 2 Receptor alpha

Alternate Names

CD25, IL-2 R alpha, IL-2Ra, IL2R alpha, IL2RA

Entrez Gene IDs

3559 (Human); 16184 (Mouse); 25704 (Rat); 403870 (Canine); 102123605 (Cynomolgus Monkey)

Gene Symbol

IL2RA

UniProt

Additional CD25/IL-2R alpha Products

Product Documents for Recombinant Cynomolgus CD25/IL-2R alpha His-tag Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Cynomolgus CD25/IL-2R alpha His-tag Protein, CF

For research use only

Loading...
Loading...
Loading...
Loading...